{"commentary":{"count":236,"free_build_floor":8,"listing_floor":3,"by_channel":{"x_thread":106,"youtube":80,"podcast":49,"x_video":1},"note":"Indexed podcasts, YouTube videos and X posts that name this trial. A report screens them, searches for more and cites what clinicians said when it is built."},"free_build":{"available":true,"how":"POST https://www.erudio.com/api/trial-requests with {\"nct_id\": \"NCT04008030\", \"email\": \"<work email>\"}. The person who owns that inbox must confirm by the emailed link; agents cannot confirm. The result is the report's public preview; the full report is still bought."},"name":"CheckMate 8HW","nct_id":"NCT04008030","offer":{"currency":"USD","how":"Order at https://www.erudio.com/contact?report=checkmate-8hw-nct04008030. The price is fixed at order. We build the report after the order and deliver it when it passes our checks; if it cannot be built to our standard, nothing is charged.","price_usd":1950,"size":"deep","size_rule":"Deep: 41+ commentary sources"},"registry":{"acronym":"CheckMate 8HW","arms":[{"description":null,"label":"Arm A: Nivolumab Monotherapy","type":"EXPERIMENTAL"},{"description":null,"label":"Arm B: Nivolumab + Ipilimumab Combination","type":"EXPERIMENTAL"},{"description":"Participants in Arm C would be allowed to receive Nivolumab + Ipilimumab if they progress","label":"Arm C: Investigator's Choice Chemotherapy","type":"ACTIVE_COMPARATOR"}],"collaborators":["Ono Pharmaceutical Co., Ltd."],"completion_date":{"date":"2027-03-23","type":"ESTIMATED"},"conditions":["Metastatic Colorectal Cancer"],"enrollment":{"count":839,"type":"ACTUAL"},"has_results":true,"interventions":[{"name":"Ipilimumab","type":"BIOLOGICAL"},{"name":"Oxaliplatin","type":"DRUG"},{"name":"Leucovorin","type":"DRUG"},{"name":"Fluorouracil","type":"DRUG"},{"name":"Irinotecan","type":"DRUG"},{"name":"Bevacizumab","type":"DRUG"},{"name":"Cetuximab","type":"DRUG"},{"name":"Nivolumab","type":"BIOLOGICAL"}],"last_update":"2026-08-20","lead_sponsor":"Bristol-Myers Squibb","official_title":"A Phase 3 Randomized Clinical Trial of Nivolumab Alone, Nivolumab in Combination With Ipilimumab, or Investigator's Choice Chemotherapy in Participants With Microsatellite Instability High (MSI-H) or Mismatch Repair Deficient (dMMR) Metastatic Colorectal Cancer","overall_status":"ACTIVE_NOT_RECRUITING","phases":["PHASE3"],"primary_completion_date":{"date":"2024-08-28","type":"ACTUAL"},"primary_outcomes":[{"measure":"Progression-free Survival (PFS) by Blinded Independent Review Center (BICR) - Arm B vs. Arm A All Lines Centrally Confirmed MSI-H/dMMR","timeFrame":"From date of randomization to the date of first objectively documented disease progression or death due to any cause, whichever occurs first (Up to approximately 60 months)"},{"measure":"Progression-free Survival (PFS) by Blinded Independent Review Center (BICR) - Arm B vs. Arm C 1L Participants Centrally Confirmed MSI-H/dMMR","timeFrame":"From date of randomization to the date of first objectively documented disease progression or death due to any cause, whichever occurs first (Up to approximately 32 months)"}],"references":[{"citation":"Andre T, Elez E, Lenz HJ, Jensen LH, Touchefeu Y, Van Cutsem E, Garcia-Carbonero R, Tougeron D, Mendez GA, Schenker M, de la Fouchardiere C, Limon ML, Yoshino T, Li J, Manzano Mozo JL, Dahan L, Tortora G, Chalabi M, Goekkurt E, Braghiroli MI, Joshi R, Cil T, Aubin F, Cela E, Chen T, Lei M, Jin L, Blum SI, Lonardi S. Nivolumab plus ipilimumab versus nivolumab in microsatellite instability-high metastatic colorectal cancer (CheckMate 8HW): a randomised, open-label, phase 3 trial. Lancet. 2025 Feb 1;405(10476):383-395. doi: 10.1016/S0140-6736(24)02848-4. Epub 2025 Jan 25.","pmid":"39874977","type":"DERIVED"},{"citation":"Andre T, Elez E, Van Cutsem E, Jensen LH, Bennouna J, Mendez G, Schenker M, de la Fouchardiere C, Limon ML, Yoshino T, Li J, Lenz HJ, Manzano Mozo JL, Tortora G, Garcia-Carbonero R, Dahan L, Chalabi M, Joshi R, Goekkurt E, Braghiroli MI, Cil T, Cela E, Chen T, Lei M, Dixon M, Abdullaev S, Lonardi S; CheckMate 8HW Investigators. Nivolumab plus Ipilimumab in Microsatellite-Instability-High Metastatic Colorectal Cancer. N Engl J Med. 2024 Nov 28;391(21):2014-2026. doi: 10.1056/NEJMoa2402141.","pmid":"39602630","type":"DERIVED"}],"start_date":{"date":"2019-08-05","type":"ACTUAL"},"study_type":"INTERVENTIONAL","title":"A Study of Nivolumab, Nivolumab Plus Ipilimumab, or Investigator's Choice Chemotherapy for the Treatment of Participants With Deficient Mismatch Repair (dMMR)/Microsatellite Instability High (MSI-H) Metastatic Colorectal Cancer (mCRC)","url":"https://clinicaltrials.gov/study/NCT04008030"},"report":null,"schema_id":"erudio.trial_listing","schema_version":"2.0","state":"listed","state_text":"No report yet. It can be ordered.","url":"https://www.erudio.com/trials/checkmate-8hw-nct04008030"}